Fountain Life Secures $18M Funding Round
Fountain Life a longevity company co-founded by Tony Robbins and Peter Diamandis, recently announced securing $18 million in funding. This fresh investment will drive their mission to revolutionize healthcare and extend the human lifespan. Specifically the company aims to detect and address health issues early promoting proactive and preventative care.
The Vision Behind Fountain Life
Fountain Life focuses on leveraging cutting-edge technologies to enhance longevity and overall well-being. Their approach involves:
Peter Diamandis – Co-founder & Executive Chairman
- As a serial entrepreneur physician and former leader of the XPRIZE Foundation and Singularity University Diamandis brings his signature blend of tech optimism and exponential thinking to Fountain Life. He focuses on transforming healthcare from reactive to predictive and preventative, leveraging AI genomics and advanced diagnostics to extend healthspan.
- He shares this vision publicly calling Fountain Life a platform where breakthroughs like early cancer detection and genomic medicine are made accessible to individuals positioning users as CEOs of their own health. Fountain Life
- In media Diamandis actively promotes longevity technologies including stem cell treatments blood filters and AI diagnostics and is also behind a revived XPrize in Longevity to incentivize breakthroughs in human aging.
Fountain Life What They’re Building Together
The company also collaborates with initiatives like the Global Wellness Institute’s Wellness Moonshot, aiming to eradicate preventable disease through behavior change and global wellness education. Diamandis and Robbins are integral in steering these efforts.
Founded in 2020 Fountain Life emerged from a merger between Dr. Bill Kapp’s Longevity Performance Center and Fountain Therapeutics an initiative that also involved both Diamandis and Robbins. Kapp leads as CEO while Diamandis and Robbins serve on the board shaping strategy and vision.
The company has raised significant capital $80M in Series A and $18M in Series B while expanding across multiple U.S. cities and continuing to scale its longevity-focused services.
Fountain Life offers an AI-backed data-driven platform that blends preventive diagnostics biomarker tracking and precision medicine. Notably its services range from full-body MRIs to regenerative therapies such as stem cell and peptide treatments.
